Shockwave Medical (BMV:SWAV *) - Prezzo delle azioni, notizie e analisi

SWAV * Panoramica delle azioni

A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. Maggiori dettagli

SWAV * analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	3/6
Prestazioni passate	4/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 8.7% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 13.48% all'anno

Gli utili sono cresciuti del 177.1% nell'ultimo anno

Analisi del rischio

Elevato livello di guadagni non monetari

Le azioni sono altamente illiquide

Gli azionisti sono stati diluiti nell'ultimo anno

Shockwave Medical, Inc. Concorrenti

Inspire Medical Systems

NYSE:INSP

US$5.5b

TransMedics Group

NasdaqGM:TMDX

US$2.6b

APT Medical

SHSE:688617

CN¥35.4b

Globus Medical

NYSE:GMED

US$11.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Shockwave Medical
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$3,700.00
Massimo di 52 settimane	US$5,111.53
Minimo di 52 settimane	US$3,700.00
Beta	1.01
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	-23.40%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-16.56%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	SWAV *	MX Medical Equipment	MX Mercato
7D	0%	0%	0%
1Y	-23.4%	0%	0%

Ritorno vs Industria: SWAV * ha avuto una performance inferiore rispetto al MX Medical Equipment che ha registrato un rendimento 14.8 % nell'ultimo anno.

Rendimento vs Mercato: SWAV * ha avuto una performance inferiore al mercato MX che ha registrato un rendimento -4 % nell'ultimo anno.

Volatilità dei prezzi

Is SWAV *'s price volatile compared to industry and market?
SWAV * volatility
SWAV * Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: SWAV * non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di SWAV * nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	1,001	Doug Godshall	shockwavemedical.com

Shockwave Medical, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Shockwave Medical con la sua capitalizzazione di mercato?
SWAV * statistiche fondamentali
Capitalizzazione di mercato	Mex$110.74b
Guadagni(TTM)	Mex$4.17b
Ricavi(TTM)	Mex$11.49b

26.5x

Rapporto P/E

9.6x

Rapporto P/S

SWAV * è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SWAV * Conto economico (TTM)
Ricavi	US$671.28m
Costo del fatturato	US$87.57m
Profitto lordo	US$583.70m
Altre spese	US$339.82m
Guadagni	US$243.88m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	6.61
Margine lordo	86.95%
Margine di profitto netto	36.33%
Rapporto debito/patrimonio netto	121.6%

Come si è comportato SWAV * nel lungo periodo?

Vedi performance storica e confronto

SWAV * Panoramica delle azioni

Premi

Analisi del rischio

Shockwave Medical, Inc. Concorrenti

NYSE:INSP

US$5.5b

NasdaqGM:TMDX

US$2.6b

SHSE:688617

CN¥35.4b

NYSE:GMED

US$11.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Recent updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Chief Accounting Officer recently sold Mex$22m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022

ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022

Independent Director recently sold Mex$7.9m worth of stock

Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Key Executive recently sold Mex$17m worth of stock

Key Executive recently sold Mex$17m worth of stock

ShockWave Medical, Inc. Announces Executive Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ShockWave Medical, Inc. Provides Revenue Guidance for the Full Year 2022

ShockWave Medical, Inc. Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions